Coherus Is Confident After US Ranibizumab Filing

Targeting Around 10% Share On Adalimumab

 
• By Aidan Fry
Eye
Cojerus is confident of being int he vanguard of biosimilar rivals to Roche's Lucentis ophthalmic blockbuster • Source: Shutterstock

More from Biosimilars

More from Products